๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› New Delhi
Clinical trial register · India

Clinical Trials in New Delhi

Every study on the ClinicalTrials.gov registry that lists a site in India and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 1123 matching records held by the registry are in this view. Synced 21 Sep 2026, 03:16 UTC
1123
Studies in scope
all four open statuses
610
Recruiting now
open to new participants
222
Lead sponsors
across recruiting studies
Top sites
New Delhi 332 Mumbai 259 Hyderabad 237 Bangalore 193 Pune 189
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Institute of Liver and Biliary Sciences, India46 AstraZeneca38 Novartis Pharmaceuticals22 Bristol-Myers Squibb18 Eli Lilly and Company17
Site location
New Delhi332 Mumbai259 Hyderabad237 Bangalore193 Pune189
All 274 locations
Target enrolment
to
332 of 1123 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Indian sites
Start
Active, closed
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
NCT06616194Migraine
Pfizer
Phase 3
200
Gurugram, Mangalore, Nashik, New Delhi
2024-11-15
Recruiting
LIVERAGEโ„ข - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
NCT06632457Metabolic Dysfunction Associated Steatohepatitis
Boehringer Ingelheim
Phase 3
1,590
Ahemdabad, Chandigarh, Hyderabad, Afzalgunj, Jaipur, Lucknow, Nagpur, New Delhi, Rohtak
2024-11-12
Not yet open
Daily Versus Alternate Day Plasma Exchange in Wilson Disease With Acute Liver Failure in Children
NCT06698991Acute Liver Failure, Wilson Disease
Institute of Liver and Biliary Sciences, India
Not applicable
20
New Delhi
2024-11-10
Not yet open
Genetic Variants Associated With the Risk of Gall Stones and Cirrhosis.
NCT06679738Liver Cirrhosis, Gall Stone
Institute of Liver and Biliary Sciences, India
Observational
50
New Delhi
2024-11-10
Recruiting
LIVERAGEโ„ข: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis
Boehringer Ingelheim
Phase 3
1,800
Ahemdabad, Chandigarh, Hyderabad, Afzalgunj, Jaipur, Lucknow, Mohali, Nagpur, New Delhi
2024-10-14
Recruiting
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
NCT06470048Diffuse Cutaneous Systemic Sclerosis
Novartis Pharmaceuticals
Phase 2
200
Kochi, Mumbai, New Delhi, Jaipur
2024-10-09
Recruiting
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression โ‰ฅ 1%
NCT06561386Non-small Cell Lung Cancer
Bristol-Myers Squibb
Phase 3
1,000
Badsa, Bengaluru, Thiruvananthapuram, Mumbai, New Delhi, Secunderabad, Varanasi, Howrah
2024-10-07
Active, closed
A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent ฮฒ-thalassemia, Using MRI Scans to Measure Iron Levels in the Body
NCT06421636Non-Transfusion Dependent Beta-Thalassemia (NTDT)
Regeneron Pharmaceuticals
Phase 2
19
Ahmedabad, Surat, Kochi, Mumbai, New Delhi, Jaipur
2024-09-30
Recruiting
Effect of Laser Photobiomodulation in Improving Mouth Opening in Oral Submucous Fibrosis
NCT06639009Oral Submucous Fibrosis
Dr. Shalini Gupta
Not applicable
315
New Delhi
2024-09-01
Recruiting
First in Human Multicenter Open Name Dose-increase, Consolidation Method to Study Safety Drug-level in Blood & Drug Metabolism Clinical Activity of Oral JBI-778 in Lung Cancer Patients With, Without Brain Metastasis IDH Mutated WHO Grade 3,4 Recurrent Glioma, Salivary Glands Tumor
NCT07755397NSCLC Patients With EGFR Activating Mutation, Adenoid Cystic Carcinoma Metastatic, Adenoid Cystic Carcinoma of the Head and Neck
Jubilant Therapeutics India Limited
Phase 1
30
Surat, Bangalore, Mumbai, Nashik, Thane, New Delhi
2024-08-26
Recruiting
Effect of Yoga in Chronic Insomnia
NCT07419152Chronic Insomnia
All India Institute of Medical Sciences
Not applicable
72
New Delhi
2024-08-14
Recruiting
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
NCT06380751Advanced Breast Cancer
AstraZeneca
Phase 3
788
Delhi, Kolkata, Lucknow, Mumbai, Mysuru, Nagpur, Nashik, New Delhi
2024-08-01
By invitation
Long-term Safety and Tolerability of BHV-7000
NCT06443463Focal Epilepsy
Biohaven Therapeutics Ltd.
Phase 2
660
Hyderabad, Mangalore, Mumbai, Nagpur, New Delhi
2024-07-30
Recruiting
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
NCT06282575Biliary Tract Cancer
Jazz Pharmaceuticals
Phase 3
286
Belagavi, Mumbai, Nashik, Hyderabad, Varanasi, New Delhi
2024-07-19
Recruiting
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
NCT06226883Inflammatory Bowel Diseases, Crohn's Disease
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Phase 2
385
Ahmedabad, Bhubaneswar, Chennai, Coimbatore, Jaipur, Kochi, Ludhiana, New Delhi
2024-07-18
Recruiting
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)
NCT06024746Heart Failure
Colorado Prevention Center
Phase 3
1,500
Ahmedabad, Bangalore, Nagpur, New Delhi
2024-07-09
Recruiting
Study of WAL0921 in Patients With Glomerular Kidney Diseases
NCT06466135Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease, Primary Immunoglobulin A Nephropathy
Walden Biosciences
Phase 2
96
Raipur, Nadiฤd, Vadodara, Bangalore, Pune, Sambhajinagar, New Delhi, Patparganj
2024-07-02
Recruiting
A Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 in Participants With Acute Pancreatitis
NCT06080789Acute Pancreatitis
Panafina, Inc.
Phase 2
36
Kochi, Vellore, Chandigarh, Delhi, New Delhi
2024-06-28
Active, closed
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
NCT06356129Large B-cell Lymphoma
Celgene
Phase 3
850
Belagavi, Kochi, Mumbai, New Delhi, Howrah, New Town
2024-06-19
Recruiting
Diabetes-Centered Evaluation of Revascularization Strategy of Functional and Imaging-CombiNEd State-of-the-Art Percutaneous Coronary Intervention or Coronary-Artery Bypass Grafting in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease
NCT05831085Coronary Artery Stenosis
Duk-Woo Park, MD
Not applicable
1,500
Bathinda, Gurugram, New Delhi
2024-06-14
Active, closed
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
NCT06305754Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC
Phase 3
550
Gurugram, Mumbai, New Delhi
2024-06-11
Active, closed
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)
NCT06472076Lung Cancer, Non-Small Cell
GlaxoSmithKline
Phase 3
88
Gokul Shirgoan, Apex Wellness Hospital, Bangalore, Belagavi, Bhubaneswar, Gurgaon, New Delhi
2024-06-10
Recruiting
Music Therapy for Rehabilitation in Post-stroke Non-fluent Aphasia: the Indian Adaptation
NCT06323330Stroke Rehabilitation, Aphasia, Broca
All India Institute of Medical Sciences
Not applicable
60
New Delhi, Delhi
2024-06-01
Recruiting
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) โ‰ฅ50% (MK-1084-004/KANDLELIT-004)
NCT06345729Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
600
Mumbai, New Delhi
2024-05-24
Recruiting
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
NCT06133972Systemic Lupus Erythematosus
Novartis Pharmaceuticals
Phase 3
550
Ahmedabad, Kozhikode, Kolhฤpur, Nagpur, Nashik, Pune, New Delhi
2024-05-21
Rows per page Showing 151–175 of 332
Previous 5 6 7 8 9 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Indian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 21 September 2026. https://priyalifescience.com/clinical-trials-india/city/new-delhi

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.